Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sage rapeutics

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade

Sage Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

How These Biotech Players Could Help Treat Covid-Fueled Depression

How These Biotech Players Could Help Treat Covid-Fueled Depression

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Investors Business Daily

8 Analysts Have This to Say About Sage Therapeutics

8 Analysts Have This to Say About Sage Therapeutics

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Sage Therapeutics Earnings Perspective: Return On Capital Employed

According to data from Benzinga Pro, during Q1, Sage Therapeutics's (NASDAQ:SAGE) reported sales totaled $1.58 million. Despite a 2.13% increase in earnings, the company posted a loss of $122.06 million.

Analyst Ratings for Sage Therapeutics

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Sage Therapeutics: Q1 Earnings Insights

Sage Therapeutics (NASDAQ:SAGE) reported its Q1 earnings results on Tuesday, May 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Sage Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know

Sage Therapeutics (NASDAQ:SAGE) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Sage Therapeutics

Expert Ratings For Sage Therapeutics

Sage Therapeutics (NASDAQ:SAGE) has observed the following analyst ratings within the last quarter:

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Advanced Micro Devices

Dell Technologies

Coinbase Global

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

303,601 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play